Advertisement
Loading...

Sino Biopharmaceutical Limited

1177.HKHKSE
Healthcare
Biotechnology
HK$4.95
HK$-0.04(-0.80%)
Hong Kong Market is Open • 09:41
Advertisement

Sino Biopharmaceutical Limited (1177.HK) Stock Competitors & Peer Comparison

See (1177.HK) competitors and their performances in Stock Market.

Peer Comparison Table: Biotechnology Industry

Detailed financial metrics including price, market cap, P/E ratio, and more.

SymbolPriceChange %Market CapP/E RatioEPSDividend Yield
1177.HKHK$4.99+3.74%89.2B33.27HK$0.15+1.80%
6160.HKHK$176.80+0.97%238.5B66.72HK$2.65N/A
1801.HKHK$83.35+11.36%144.6B154.35HK$0.54N/A
2269.HKHK$33.34+2.96%137.8B24.88HK$1.34N/A
9926.HKHK$118.10+6.97%108.6B-83.76-HK$1.41N/A
6990.HKHK$462.00+3.36%107.7B-243.16-HK$1.90N/A
3759.HKHK$17.52+0.75%47.8B15.93HK$1.10+1.25%
1530.HKHK$18.50+7.25%46.3B4.67HK$3.96+1.35%
9995.HKHK$82.65+4.69%45.7B55.47HK$1.49N/A
2696.HKHK$68.50+8.21%37.2B39.37HK$1.74N/A
1

Stock Comparison

Select a stock to compare (requires JavaScript). Showing default comparison.

1177.HK vs 6160.HK Comparison June 2026

1177.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 1177.HK stands at 89.2B. In comparison, 6160.HK has a market cap of 238.5B. Regarding current trading prices, 1177.HK is priced at HK$4.99, while 6160.HK trades at HK$176.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

1177.HK currently has a P/E ratio of 33.27, whereas 6160.HK's P/E ratio is 66.72. In terms of profitability, 1177.HK's ROE is +0.07%, compared to 6160.HK's ROE of +0.12%. Regarding short-term risk, 1177.HK is more volatile compared to 6160.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 1177.HK.Check 6160.HK's competition here

Stock price comparison of stocks in the Healthcare Sector

Loading...

Frequently Asked Questions